Astrana Health Raises Price Target to $41 After $965M Q1 Revenues, $0.74 EPS Beat
ASTH•Astrana Health reported Q1 revenues of $965.10 million, up from $620.39 million a year earlier, marking its fourth consecutive quarter of revenue-beating performance. Quarterly EPS reached $0.74, more than double the $0.29 consensus estimate, prompting Needham to raise its price target to $41 from $30 while keeping a Buy rating.
1. Q1 2026 Financial Results
Astrana Health posted first-quarter 2026 revenues of $965.10 million, up 55.6% from $620.39 million in the year-ago period, marking its fourth straight quarter of revenue outperformance. EPS rose to $0.74, beating the $0.29 consensus by 155% and up from $0.14 a year earlier.
2. Analyst Price Target Increase
On May 8, 2026, Needham raised its price target for Astrana Health to $41 from $30 and maintained its Buy rating, reflecting increased confidence in the company’s growth trajectory based on Q1 strength.
3. Stock Performance and Outlook
The company operates an integrated care delivery and financial accountability model and holds a market capitalization near $1.99 billion. Shares traded around $35.74, close to a 52-week high of $38.79, while CEO Brandon Sim cited disciplined growth and strong medical cost performance as key drivers.
